A phase ΙI study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study)

BACKGROUND: We previously conducted a phase I trial for advanced colorectal cancer (CRC) using five HLA-A*2402-restricted peptides, three derived from oncoantigens and two from vascular endothelial growth factor (VEGF) receptors, and confirmed safety and immunological responses. To evaluate clinical...

Descripción completa

Detalles Bibliográficos
Autores principales: Hazama, Shoichi, Nakamura, Yusuke, Tanaka, Hiroaki, Hirakawa, Kosei, Tahara, Ko, Shimizu, Ryoichi, Ozasa, Hiroaki, Etoh, Ryuichi, Sugiura, Fumiaki, Okuno, Kiyotaka, Furuya, Takumi, Nishimura, Taku, Sakata, Koichiro, Yoshimatsu, Kazuhiko, Takenouchi, Hiroko, Tsunedomi, Ryouichi, Inoue, Yuka, Kanekiyo, Shinsuke, Shindo, Yoshitaro, Suzuki, Nobuaki, Yoshino, Shigefumi, Shinozaki, Hirokazu, Kamiya, Akira, Furukawa, Hiroyuki, Yamanaka, Takeharu, Fujita, Tomonobu, Kawakami, Yutaka, Oka, Masaaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021539/
https://www.ncbi.nlm.nih.gov/pubmed/24884643
http://dx.doi.org/10.1186/1479-5876-12-108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4021539/
https://www.ncbi.nlm.nih.gov/pubmed/24884643
http://dx.doi.org/10.1186/1479-5876-12-108

Ejemplares similares